Sukhbir Lal Khokra (Sukhbir Lal)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Molecular Docking

Infectious Diseases

Structure Activity Relationship

Silver Nanoparticles

Top Venues

Future medicinal chemistry

Assay and drug development technologies

This page only lists publications with an associated author ORCID identifier.

Publications

Sangeeta Verma, Sukhbir Lal Khokra, Rakesh Narang
Expanding potential of quinoline hydrazide/hydrazone derivatives as anticancer agents. Future medicinal chemistry 16 (13) (2024)
Sangeeta Verma, Sukhbir Lal Khokra, Rakesh Narang
Expanding potential of quinoline hydrazide/hydrazone derivatives as anticancer agents. Future medicinal chemistry 16 (13) (2024)
Sangeeta Verma, Sukhbir Lal Khokra, Rakesh Narang
Expanding potential of quinoline hydrazide/hydrazone derivatives as anticancer agents. Future medicinal chemistry 16 (13) (2024)
Sangeeta Verma, Sukhbir Lal Khokra, Rakesh Narang
Expanding potential of quinoline hydrazide/hydrazone derivatives as anticancer agents. Future medicinal chemistry (2024)
Sangeeta Verma, Sukhbir Lal Khokra, Rakesh Narang, Kalvatala Sudhakar
Quinoline Hydrazide/Hydrazone Derivatives: Recent Insights on Antibacterial Activity and Mechanism of Action. ChemMedChem (2023)
Sangeeta Verma, Sukhbir Lal Khokra, Rakesh Narang, Kalvatala Sudhakar
Quinoline Hydrazide/Hydrazone Derivatives: Recent Insights on Antibacterial Activity and Mechanism of Action. ChemMedChem 18 (5) (2023)
Sangeeta Verma, Sukhbir Lal Khokra, Rakesh Narang, Kalvatala Sudhakar
Quinoline Hydrazide/Hydrazone Derivatives: Recent Insights on Antibacterial Activity and Mechanism of Action. ChemMedChem 18 (5) (2023)
Sangeeta Verma, Sukhbir Lal Khokra, Rakesh Narang, Kalvatala Sudhakar
Quinoline Hydrazide/Hydrazone Derivatives: Recent Insights on Antibacterial Activity and Mechanism of Action. ChemMedChem 18 (5) (2023)
Manish Kumar, Isha Rani, Somdutt Mujwar, Rakesh Narang, Manish Devgun, Sukhbir Lal Khokra
In-Silico Design, Synthesis, and Pharmacological Evaluation of Oxadiazole-Based Selective Cyclo-oxygenase-2 Inhibitors. Assay and drug development technologies 21 (4) (2023)